Liminatus Pharma, Inc Class A Common Stock
Yahoo Finance • 10 days ago
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
Liminatus Pharma Inc. FULLERTON, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company") today announced that its board of directors has adopted resolutions approving a reverse stock... Full story
Yahoo Finance • 16 days ago
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
Liminatus Pharma Inc. FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biopharmaceutical company developing novel therapies for cancer and other serious diseases,... Full story
- IXIC
Mentioned:
Yahoo Finance • 10 months ago
Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation
LA PALMA, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a clinical-stage immuno-oncology company developing next-generation CD47-blockade therapies, announced today that it has entered into a Memorandum... Full story
Yahoo Finance • last year
Wondering what's happening in today's pre-market session?
Wondering what's happening in Friday's pre-market session? Find an overview in this article. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT EEIQ [https://www.chartmill.com/stock/quote/EEIQ/profile] 127.0% EPICQUEST... Full story
Yahoo Finance • last year
Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative
LA PALMA, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced plans for a strateg... Full story
Yahoo Finance • last year
Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy
LA PALMA, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced it has entered into... Full story
Yahoo Finance • last year
Get insights into the top gainers and losers of Thursday's pre-market session.
Before the US market kicks off on Thursday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] GAINERS TICKER CHANGE COMMENT LIDR [https://www.chartmill.com/st... Full story
Yahoo Finance • last year
Liminatus gains amid review to consider digital assets for treasury management
[Glowing dollar symbol, cryptocurrency network, neon green dollar symbol, blue blockchain links, futuristic finance tech, global economy, cyberpunk aesthetic. 3D render.] * Liminatus Pharma (NASDAQ:LIMN [https://seekingalpha.com/symbol/... Full story
Yahoo Finance • last year
Liminatus Pharma explores digital asset treasury strategy
Liminatus Pharma, Inc. (LIMN) announced it has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies in its treasury management framework. The preclinical-stage biopharmaceutical company, w... Full story
Yahoo Finance • last year
Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy
LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that it has initiat... Full story
Yahoo Finance • last year
Liminatus Pharma appoints Philip Lemons and Richard Baek to board of directors
Liminatus Pharma, Inc. (NASDAQ:LIMN), a $173 million market cap pharmaceutical company, announced Thursday that its board of directors has expanded to six members with the appointment of Philip Lemons and Richard Baek as directors, effecti... Full story
Yahoo Finance • last year
Liminatus Pharma forms consortium for pancreatic cancer diagnostic kit
Liminatus Pharma, Inc. (NASDAQ:LIMN), a $245 million market cap biotech company whose stock has declined nearly 47% in the past week, announced Wednesday that it has entered into a memorandum of understanding to form a research and develop... Full story
Yahoo Finance • last year
Liminatus Pharma stock gains on regaining compliance with Nasdaq
[A graph moving up] Richard Drury * Liminatus Pharma (NASDAQ:LIMN [https://seekingalpha.com/symbol/LIMN]) shares rose after the company said it regained compliance with Nasdaq's listing needs [https://seekingalpha.com/filing/10070728].... Full story